Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma.

Barlogie B, Smallwood L, Smith T, Alexanian R.

Ann Intern Med. 1989 Apr 1;110(7):521-5.

PMID:
2647015
2.

High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.

Dimopoulos MA, Barlogie B, Smith TL, Alexanian R.

Ann Intern Med. 1991 Dec 15;115(12):931-5.

PMID:
1952489
3.

High serum lactate dehydrogenase level predicts short survival after vincristine-doxorubicin-dexamethasone (VAD) salvage for refractory multiple myeloma.

Suguro M, Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Matsuyama T, Takezako N, Miwa A, Togawa A.

Am J Hematol. 2000 Oct;65(2):132-5.

PMID:
10996830
4.

[Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].

Marisavljević D, Bosković D, Radosević N, Elezović I, Tomin D, Gotić M, Antunović P.

Srp Arh Celok Lek. 1996 Nov-Dec;124(11-12):292-6. Serbian.

PMID:
9132962
5.

Total therapy with tandem transplants for newly diagnosed multiple myeloma.

Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A, Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D, Ayers D, Cheson B, Crowley J.

Blood. 1999 Jan 1;93(1):55-65.

6.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
7.

Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features.

Niesvizky R, Siegel D, Glassman J, Straus D, Fine J, Lyons L, Michaeli J.

Leuk Lymphoma. 2002 Mar;43(3):607-12.

PMID:
12002766
8.

Prognostic factors with high-dose melphalan for refractory multiple myeloma.

Barlogie B, Alexanian R, Smallwood L, Cheson B, Dixon D, Dicke K, Cabanillas F.

Blood. 1988 Dec;72(6):2015-9.

11.

Prognostic value of serum lactic dehydrogenase (S-LDH) in multiple myeloma.

Simonsson B, Brenning G, Källander C, Ahre A.

Eur J Clin Invest. 1987 Aug;17(4):336-9.

PMID:
3117570
12.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijaert MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group.

Blood. 2003 Mar 15;101(6):2144-51. Epub 2002 Nov 27.

13.

Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.

Vela-Ojeda J, García-Ruiz Esparza MA, Rosas-Cabral A, Padilla-González Y, García-Chávez J, Tripp-Villanueva F, Sánchez-Cortés E, Ayala-Sánchez M, García-León LD, Montiel-Cervantes L, Rubio-Borja ME.

Ann Hematol. 2002 Jul;81(7):362-7. Epub 2002 Jun 25.

PMID:
12185504
14.

Treatment of myeloma.

Smith ML, Newland AC.

QJM. 1999 Jan;92(1):11-4. Review.

PMID:
10209667
15.

Therapy of primary resistant and relapsed multiple myeloma.

Barlogie B, Alexanian R.

Onkologie. 1986 Aug;9(4):210-4.

PMID:
3531948
16.

[Drug-resistant multiple myeloma with high serum levels of lactate dehydrogenase and neutrophil infiltration in pleural effusion].

Kozawa M, Hata H, Kawaguchi T, Tsuji N, Mori S, Harada N, Nakahashi E, Sakata K, Matsuzaki H, Takatsuki K.

Rinsho Ketsueki. 1994 Jan;35(1):49-53. Japanese.

PMID:
8139102
18.

Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.

Lokhorst HM, Sonneveld P, Cornelissen JJ, Joosten P, van Marwijk Kooy M, Meinema J, Nieuwenhuis HK, van Oers MH, Richel DJ, Segeren CN, Veth G, Verdonck LF, Wijermans PW.

Bone Marrow Transplant. 1999 Feb;23(4):317-22.

19.

Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.

Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, Mann G, Chott A, Ebell W, Klingebiel T, Graf N, Kremens B, Müller-Weihrich S, Plüss HJ, Zintl F, Henze G, Riehm H.

Blood. 1999 Nov 15;94(10):3294-306.

20.

Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.

Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, Kokoris SI, Gribabis DA, Dimopoulou MN, Angelopoulou MK, Pangalis GA.

Eur J Haematol. 2004 Apr;72(4):252-8.

PMID:
15089762

Supplemental Content

Support Center